STATCenter·
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Read at STAT →
Health · 1 sources covering this
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/323e1a8e67fdb3818da26e2c65fc221a29081528" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug"></iframe>
